On October 21, 2020, Longevity Acquisition Corporation entered into an Agreement and Plan of Merger with 4D Pharma PLC and Dolphin Merger Sub Limited and a wholly-owned subsidiary of 4D Pharma. Concurrent with the execution of the Merger Agreement and the receipt of the proceeds from the Note, Messrs. Matthew Chen resigned from their positions of Chief Executive Officer. On the same date, the Board appointed Alex Lyamport as CEO. Mr. Lyamport has been a Director and CFO of Navigation Acquisition Corp. since January 2018 and a Director at Navigator Principal Investors, LLC since 2012.